We appreciate and welcome the remarks of Boriani and colleagues on our competing risk study published in Circulation. 1 Boriani et al point to heart transplantation as an outcome that occurs in competition to appropriate implantable cardioverter-defibrillator (ICD) therapy or death before appropriate ICD therapy. We agree on this point and report that 7 patients underwent heart transplantation (5 with dilated cardiomyopathy and 2 with coronary artery disease). Two of these patients died in the postoperative period and before ever using the ICD device. Both were thus classified as cardiac death ( Table 2) . Of the 5 transplantation survivors, 2 never used their device before undergoing transplantation and both observations were censored at the time of transplantation. The other 3 transplantation survivors all had either ventricular tachycardia or fast ventricular tachycardia episodes before undergoing transplantation and thus experienced the event of interest. As a result, only 2 subjects had contributed to the competing risk event "heart transplantation." However, in countries with larger organ availability, heart transplantation might contribute in a more relevant manner.
Patients with an ICD implanted for secondary prevention experienced appropriate ICD therapies more frequently than patients with an ICD implanted for primary prevention. Boriani et al argue that this larger "benefit" might be an artifact due to the potentially lower cutoff rates for ventricular tachycardia detection in secondary prevention patients. Although this might be a potential explanation for the association of secondary prevention with ventricular tachycardia occurrence, it is of interest to report that this association was also found for ventricular fibrillation occurrence, even though the association was less strong. The rate for the detection of primary ventricular fibrillation was standardized to at least 200 bpm and was less subject to individual programming. A similar trend with larger benefits in the secondary prevention setting was found in the more recent Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) 2 and the Second Multicenter Automated Defibrillator Implantation Trial (MADIT II). 3 Lastly, we think that risk stratification and consideration of ICD replacement will be crucial in the future. Although only half of our population had Ͼ3.6 years of follow-up, none of the patients free of appropriate ICD therapy up to 6 years used the device to terminate ventricular fibrillation thereafter. Rethinking of device replacement is needed in patients who have never used their device and who have undergone ICD implantation for primary prevention of sudden cardiac death. Major research efforts are needed to develop rational replacement strategies in the growing number of older patients with changing risk profiles for appropriate ICD therapy and for prior death. 
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